Germany at a glance
- Population
- 83.5 million 2025
- Life expectancy at birth
- 80.8 years, 2024
- People aged 65 and over
- 23.7 % of people, 2025
- Health spending per person
- 6,849 US$ per person, 2024
- Doctors
- 4.53 per 1,000 people, 2022
Updated
Reviewed by Chandani Patel
Germany Antifungal Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Infection, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$99.8 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $501.6 Mn | — | — |
| 2025 (base) | $511.7 Mn | +$10.0 Mn | — |
| 2026 (forecast) | $521.9 Mn | +$10.2 Mn | +2% |
| 2027 (forecast) | $532.3 Mn | +$10.4 Mn | +4% |
| 2028 (forecast) | $543.0 Mn | +$10.6 Mn | +6.1% |
| 2029 (forecast) | $553.8 Mn | +$10.9 Mn | +8.2% |
| 2030 (forecast) | $564.9 Mn | +$11.1 Mn | +10.4% |
| 2031 (forecast) | $576.2 Mn | +$11.3 Mn | +12.6% |
| 2032 (forecast) | $587.7 Mn | +$11.5 Mn | +14.9% |
| 2033 (forecast) | $599.5 Mn | +$11.8 Mn | +17.2% |
| 2034 (forecast) | $611.5 Mn | +$12.0 Mn | +19.5% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $511.7 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $611.5 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 2.0% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Drug class, infection and end user (see all) |
| Key players | Pfizer Inc., Astellas Pharma Inc., Merck & Co., Inc., Mundipharma, Basilea Pharmaceutica (see all) |
| Regulator in Germany | BfArMSource: Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Antifungal drugs treat infections caused by fungi, from skin and nail infections to life-threatening infections in hospital patients.
Key segments of the antifungal Drugs market include drug class (Azoles, Echinocandins and Polyenes) and infection (Superficial and Invasive).
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the antifungal Drugs market.
New vaccines, rapid tests and public-private funding for neglected diseases give the antifungal Drugs market room to grow, especially in Asia, Africa and Latin America.
Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the antifungal Drugs market.
The antifungal Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by BfArM or, for vaccines and blood products, the Paul-Ehrlich-Institut.[1] Most people have statutory health insurance; the Federal Joint Committee (G-BA) decides what it covers and rates the added benefit of new medicines.[2]
[1] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
[2] Federal Joint Committee (G-BA). Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for antifungal Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Germany.
What doctors and scientists are doing in Antifungal Drugs right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 17 Nov 2026.
From our blog
Germany
Germany
Germany
Germany
Germany
Germany
Medical Devices · Germany
Medical Devices · Germany
Digital Health · Germany
Medical Devices · Germany
Healthcare Services · Germany
OTC & Nutraceuticals · Germany